# Phase II Study of RC1416 Injection in COPD

> **NCT07402551** · PHASE2 · RECRUITING · sponsor: **Nanjing RegeneCore Biotech Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** RC1416
- **DRUG:** RC1416 Placebo

## Key facts

- **NCT ID:** NCT07402551
- **Lead sponsor:** Nanjing RegeneCore Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-08-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402551, "Phase II Study of RC1416 Injection in COPD". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07402551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*